U&G Biotechnology (Hangzhou) Co., Ltd.

Customized Diagnostic Products and Services

A high-tech enterprise specializing in the field of molecular diagnostics, integrating R&D, manufacturing, and sales under one roof.

了解更多

U&G Biotechnology (Hangzhou) Co., Ltd.

Explore life sciences, Protect human health

The company specializes in the R&D and production of core raw materials for in vitro diagnostics, and offers services such as custom enzyme sourcing, OEM manufacturing, and process optimization tailored to in vitro diagnostic reagent manufacturers.

了解更多
scroll down

U&G Biotechnology (Hangzhou) Co., Ltd.

Rooted in China, serving the world!

U&G Biotechnology (Hangzhou) Co., Ltd. established in 2020, is a high-tech enterprise specializing in the field of molecular diagnostics, integrating R&D, manufacturing, and sales under one roof. Leveraging its independently built innovative biotechnology R&D center and a robust team of experts, U&G Bio is dedicated to delivering premium-quality core materials, cutting-edge innovative solutions, and customized services to the life science research and in vitro diagnostic (IVD) industries. Upholding a customer-first service philosophy and committed to the product goals of "ultra-pure quality and exceptional innovation," the company continuously strives to enhance product excellence.

2020 Year

The company was established in 2020.

32 +

Achieving superior mutations in 32 types of tool enzymes

10 +

Each product undergoes more than 10 QC checks.

View details

New Product Recommendation

image

Library Amplification

High-Fidelity PCR

2X GeniuSTAR Max Fast PCR Master Mix

High-fidelity enzyme premix for NGS sequencing

Reverse Transcription Premix (for qPCR Use Only)

GeniuScript III RT Kit for qPCR (gDNA Removal)

QPCR-specific reverse transcription premix for genome removal

Bestselling Products

Providing ultra-pure, stable enzyme products with excellent performance, along with specialized custom services.

image

News & Information

Explore life sciences, safeguard human health—learn more about U&G Biotechnology News!

image

U&G Biotechnology receives the National High-Tech Enterprise Certification!

On December 26, 2024, the Office of the National Leading Group for the Management of High-Tech Enterprise Recognition released the "List of Registered High-Tech Enterprises Reported by Zhejiang Province's Designated Institutions in 2024." YooGene Biotech has officially been awarded the national High-Tech Enterprise certification! This is not only the highest recognition of our past efforts but also a promising outlook for the exciting journey ahead.

11 Feb,2025

Cybersecurity for the People

The Ministry of Public Security attaches great importance to cracking down on and addressing illegal activities related to "online water armies." Relying on the targeted "Clean Web 2024" campaign, it is launching a full-scale offensive, focusing on prominent criminal activities such as spreading rumors to drive traffic, manipulating public opinion for extortion, inflating metrics to control reviews, and offering paid services to delete online posts. Nationwide, public security authorities have been deployed to carry out comprehensive enforcement efforts.

11 Feb,2025

Great news! U&G Biotechnology has successfully achieved ISO 9001 and ISO 13485 quality management system certifications.

In October 2023, after a two-phase audit by review experts from Beijing Guoyi Xiehuaguang Certification Co., Ltd., U&G Biotechnology (Hangzhou) Co. Ltd successfully achieved ISO 9001:2015 and ISO 13485:2016 certifications and received the corresponding certificates. This milestone underscores that our company’s quality management system now meets international standards and regulatory requirements.

08 Nov,2023

The National Health Commission has recently issued a document—Announcing the "14th Five-Year Plan for the Development of Clinical Specialty Capabilities."

On October 18, to further strengthen clinical specialty capacity building and fully leverage its critical role in driving high-quality development of public hospitals, the National Health Commission organized the drafting and release of the "National Clinical Specialty Capacity Building Plan for the 14th Five-Year Period," providing guidance to regions across the country on how to effectively advance clinical specialty development during this period.

22 Oct,2021